Last Update 04 Apr 26

Fair value Decreased 13%

HUM: Medicare Advantage Margin Recovery Will Drive Future Repricing Potential

Humana's updated analyst price target has shifted down from $348.00 to about $302.11, as analysts factor in lower target ranges across the Street, a higher discount rate, and cautious views on Medicare Advantage margins and earnings visibility.

Analyst Commentary

Recent Street research on Humana reflects a broadly cautious stance, with several firms cutting price targets and reassessing Medicare Advantage earnings power. Much of the focus is on margin visibility, the impact of Centers for Medicare & Medicaid Services rate decisions, and management's expectations for Individual Medicare Advantage profitability.

Several firms have lowered price targets into a tighter range and shifted or reaffirmed more neutral ratings such as Equal Weight or Hold. Key issues flagged include uncertainty around Medicare Advantage cost trends, the pace of margin improvement, and the profitability of new membership growth. Some research also highlights that membership trends can create a wide range of earnings outcomes, which is feeding into more conservative modeling.

On the regulatory side, commentary around recent CMS rate notices describes them as a headwind for managed care, pointing to pressure on Medicare Advantage economics. There are also views that a quick recovery in health insurers following policy updates is unlikely, which is adding to the hesitation around near term earnings visibility and valuation support.

At the same time, there is research that frames upcoming policy developments and product level rate setting as important catalysts for sentiment. Views on Humana's ability to adjust benefits, pricing, and administrative costs across cycles remain a central part of how analysts are thinking about fair value for the shares.

Bullish Takeaways

Bullish analysts highlight a raised price target to $344, framing Humana as part of a group of government managed care names that could see earnings improvement in Medicare Advantage ahead of other segments. This supports a more constructive view on medium term valuation.
These bullish views see all managed care organization segments as offering attractive entry points, with Medicare Advantage positioned for earlier earnings recovery and Medicaid screens as having appealing valuation levels. This can underpin interest in diversified exposure to the group.
Some bullish research points to expected positive catalysts from upcoming Medicare Advantage 2027 rates. If supportive, these could help sentiment around Humana's ability to execute on margin and growth plans in that product line.
Bullish analysts also reference the broader policy backdrop, including commentary around the "Great Healthcare Plan," as removing fears of new onerous proposals for insurers, which may help reduce perceived regulatory risk embedded in current multiples.

What's in the News

A new analysis suggests former President Trump’s Medicare GLP-1 drug plan could cost insurers billions of dollars, spotlighting potential exposure for Medicare Advantage carriers that cover GLP-1 therapies (Bloomberg).
Reports indicate the Trump administration is proposing flat Medicare insurance rates in 2027, drawing attention to how future reimbursement terms might shape Medicare Advantage economics (WSJ).
House Judiciary Committee Republicans issued subpoenas to eight ACA insurers as part of a fraud probe tied to premium subsidies, with Humana mentioned among other publicly traded insurers that operate in the broader health insurance space (Axios).
Humana announced expanded value based cardiac care partnerships with CVAUSA’s Novocardia Care Solutions, Karoo Health, US Heart and Vascular and Chamber Cardio, giving eligible Individual and Group Medicare Advantage members broader access to coordinated heart health programs across multiple states.
Humana reported that from October 1, 2025 to February 18, 2026 it repurchased 502,574 shares for US$126.66m, bringing total repurchases under the February 15, 2024 buyback authorization to 1,138,910 shares for US$300m.

Valuation Changes

Fair Value: Updated analyst fair value has moved from about $348.00 to about $302.11, a reduction of roughly 13% in the modeled target level.
Discount Rate: The discount rate has risen slightly from 6.40% to about 6.98%, which generally points to a higher required return being applied to Humana's cash flows.
Revenue Growth: The revenue growth assumption has shifted from about 9.35% to about 16.28%, representing a sizable change in the modeled expectation for top line expansion.
Net Profit Margin: The net profit margin assumption has moved modestly from about 1.96% to about 2.07%, indicating a small change in the expected profitability on each $1 of revenue.
Future P/E: The future P/E multiple has been reset from about 16.47x to about 10.51x, reflecting a lower valuation multiple in the updated analysis.

0 views

Key Takeaways

Growth in Medicare Advantage and CenterWell platforms, driven by demographic trends and care initiatives, positions Humana for sustained revenue and earnings improvement.
Investments in advanced technology and value-based care enhance operational efficiency, margin expansion, and more stable, predictable profitability over time.
Heavy reliance on Medicare Advantage, evolving CMS criteria, rising medical costs, vertical integration risks, and intense competition threaten Humana’s margins, revenue growth, and market position.

Catalysts

About Humana

Provides medical and specialty insurance products in the United States.What are the underlying business or industry changes driving this perspective?

Demographic shifts from the aging U.S. population and Baby Boomer retirements are increasing the Medicare-eligible population, supporting sustained high demand for Humana’s Medicare Advantage plans and driving long-term revenue growth.
Humana’s integration of advanced technology—including AI in contact centers, telehealth, and data analytics—promises to deliver greater operating efficiencies, reducing administrative expenses and supporting higher net margins over the coming years.
The company’s continued strategic investments in value-based care, including clinical initiatives to improve Star ratings and close care gaps, are expected to result in lower medical loss ratios and stronger margin expansion as clinical performance becomes a bigger driver of reimbursement.
Ongoing expansion and maturation of the CenterWell platform (primary care, home health, and pharmacy) is expected to boost per-member-per-month payments and operating leverage as new clinics move through the J-curve, supporting both revenue and long-term earnings growth.
Humana’s execution in shifting its membership toward higher lifetime value segments, alongside growing Medicaid presence and scale advantages from consolidation, is likely to lead to more predictable earnings and improved profitability as these trends compound over multiple years.

Humana Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Humana compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Humana's revenue will grow by 16.3% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from 0.9% today to 2.1% in 3 years time.
The bullish analysts expect earnings to reach $4.2 billion (and earnings per share of $36.26) by about April 2029, up from $1.2 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $2.3 billion.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 10.5x on those 2029 earnings, down from 18.0x today. This future PE is lower than the current PE for the US Healthcare industry at 22.0x.
The bullish analysts expect the number of shares outstanding to decline by 0.08% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Humana’s significant exposure to Medicare Advantage introduces long-term risk if government reimbursement rates are reduced or regulatory changes occur, which could impair revenue growth and profitability.
The outcome and evolving criteria of the CMS Stars ratings, including ongoing litigation and uncertainty over cut points, pose risk to Humana’s ability to achieve targeted margins, potentially leading to margin compression and lower net earnings.
Challenges in medical cost management, as highlighted by mid-single-digit growth trends and higher-than-expected utilization in areas like oncology, create persistent pressure on net margins and put Humana at risk if future trends outpace their projections.
Execution risk from continued investment in vertical integration—such as CenterWell primary care and pharmacy expansion—means any missteps or underperformance could lead to elevated costs, increased capital intensity, and muted returns on invested capital, negatively impacting long-term earnings.
Heightened competition from other insurers, disruptors, and value-based care models, coupled with regulatory pushes for price transparency, may erode Humana’s pricing power, threaten market share, and constrain revenue and profit expansion over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Humana is $302.11, which represents up to two standard deviations above the consensus price target of $212.17. This valuation is based on what can be assumed as the expectations of Humana's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $333.0, and the most bearish reporting a price target of just $146.0.
In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $203.9 billion, earnings will come to $4.2 billion, and it would be trading on a PE ratio of 10.5x, assuming you use a discount rate of 7.0%.
Given the current share price of $177.83, the analyst price target of $302.11 is 41.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Humana?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Aging Population And Tech Will Shape Long-Term Medicare Care